This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zevra Therapeutics (ZVRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Zevra Therapeutics (ZVRA) points to an 117.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
by Zacks Equity Research
CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.
Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice
by Zacks Equity Research
Does Zevra Therapeutics (ZVRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
by Kinjel Shah
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 86.6% in Zevra Therapeutics (ZVRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)
by Zacks Equity Research
Zevra Therapeutics (ZVRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of 71.43% and 29.12%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of 14.29% and 4.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -71.79% and 39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -56.82% and 26.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 40% and 0.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zevra Stock Surges Close to 70% in 3 Months: Here's Why
by Zacks Equity Research
The FDA approval for ZVRA's Miplyffa (arimoclomol) capsules in September for treating Niemann-Pick disease type C drives the stock.
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
by Zacks Equity Research
Biohaven and Zevra are in the spotlight following positive updates on key candidates.
Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?
by Zacks Equity Research
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -2.13% and 8.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Journey Medical (DERM) delivered earnings and revenue surprises of -13.33% and 7.57%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Century Therapeutics (IPSC) delivered earnings and revenue surprises of 24% and 40.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
by Zacks Equity Research
The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Zevra Therapeutics (ZVRA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of 18.37% and 2.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?